Patents by Inventor Jamal El Yazal

Jamal El Yazal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Variants of RANKL protein
    Patent number: 7399829
    Abstract: The present invention relates to novel, soluble, recombinant variants RANKL (Receptor Activator of Nuclear Factor—?B Ligand) proteins, which may be expressed solubly in E. coli, variants that act as RANKL antagonists, and methods for generating the same.
    Type: Grant
    Filed: January 6, 2003
    Date of Patent: July 15, 2008
    Assignee: Xencor, Inc.
    Inventors: John R. Desjarlais, Jamal El Yazal, Rene S. Hubert, Shannon A. Marshall
  • Variants of RANKL protein
    Patent number: 7381792
    Abstract: The present invention relates to novel, soluble, recombinant RANKL (Receptor Activator of Nuclear Factor—?B Ligand) variant proteins which may be expressed solubly in E. coli, variants that have substantially reduced binding to OPG, variants that act as RANKL antagonists, and methods for generating the same.
    Type: Grant
    Filed: July 1, 2003
    Date of Patent: June 3, 2008
    Assignee: Xencor, Inc.
    Inventors: John R. Desjarlais, Rene S. Hubert, Jamal El Yazal, Shannon A Marshall
  • Thrombopoiesis-stimulating proteins having reduced immunogenicity
    Publication number: 20040121953
    Abstract: The present invention relates to variant thrombopoietin proteins that possess thrombopoiesis-stimulating activity and have reduced immunogenicity. In particular, variants of thrombopoietin with reduced ability to bind one or more human class II MHC molecules are described.
    Type: Application
    Filed: August 11, 2003
    Publication date: June 24, 2004
    Inventors: Arthur J. Chirino, Jamal El Yazal, Shannon Alicia Marshall, Peter McDonnell, Jost Vielmetter
  • Novel variants of rankl protein
    Publication number: 20040121363
    Abstract: The present invention relates to novel, soluble, recombinant RANKL (Receptor Activator of Nuclear Factor—&kgr;B Ligand) variant proteins which may be expressed solubly in E. coli, variants that have substantially reduced binding to OPG, variants that act as RANKL antagonists, and methods for generating the same.
    Type: Application
    Filed: July 1, 2003
    Publication date: June 24, 2004
    Inventors: John R. Desjarlais, Rene S. Hubert, Jamal El Yazal
  • Novel variants of RANKL protein
    Publication number: 20030219864
    Abstract: The present invention relates to novel, soluble, recombinant variants RANKL (Receptor Activator of Nuclear Factor—&kgr;B Ligand) proteins, which may be expressed solubly in E. coli, variants that act as RANKL antagonists, and methods for generating the same.
    Type: Application
    Filed: January 6, 2003
    Publication date: November 27, 2003
    Inventors: John R. Desjarlais, Rene S. Hubert, Jamal El Yazal